TOP > 外国特許検索 > Human antibody kappa-type light chain complex-containing composition and method of manufacturing the same

Human antibody kappa-type light chain complex-containing composition and method of manufacturing the same NEW

外国特許コード F170009191
整理番号 AF12-18TW
掲載日 2017年9月12日
出願国 台湾
出願番号 103128124
公報番号 201536800
出願日 平成26年8月15日(2014.8.15)
公報発行日 平成27年10月1日(2015.10.1)
優先権データ
  • 特願2013-170414 (2013.8.20) JP
発明の名称 (英語) Human antibody kappa-type light chain complex-containing composition and method of manufacturing the same NEW
発明の概要(英語) (TW201536800)
A human antibody kappa-type light chain complex-containing composition of the present invention comprises a complex which is formed by binding human antibody kappa-type light chain and at least one metal ion selected from the group consisting of a group 10 element, a group 11 element and a group 12 element, wherein the human antibody kappa-type light chain is a dimer, two C-terminal cysteines of the human antibody kappa-type light chains binds together by an interaction with the metal ion, and 0.1 mol or more of the metal ion binds to 1 mol of human antibody kappa-type light chain.
特許請求の範囲(英語) [claim1]
1. Kinds include the human antibody Kappa the constituent of light chain complex, it 徴 lay in especially contains to unify the human antibody Kappa the light chain and metallic ion complex, and this metal to substance elected, from Yu You the 10th race element, the 11th race element and 12th race element constituted over 1 of kind groups; The above human antibody Kappa light chain is the dimer, and 2 above human antibodies Kappa the C of terminal's light chain half bladder amino acid is unifies by the above metallic ion; And, each not ear the above human antibody Kappa the light link gathers above 0.1 not ear the above metallic ion.
[claim2]
2. Like request item 1 includes the human antibody Kappa the constituent of light chain complex, the above metal to substance elects, from is constituted over 1 of by the cupric ion, the nickel ion, zinc ion and Jin Lizi, the silver ion and platinum ion kind groups.
[claim3]
3. Like request item 1 or 2 include the human antibody Kappa the constituent of light chain complex, the above human antibody Kappa the light chain elects from following the group of constitution: (1) may the variation area be the sequence serial number 1 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (2) may the variation area be the sequence serial number 3 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (3) may the variation area be the sequence serial number 5 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (4) may the variation area be the sequence serial number 7 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (5) may the variation area be the sequence serial number 9 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (6) may the variation area be the sequence serial number 11 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (7) may the variation area be or this aminoacid sequence 1 either several aminoacid by in the sequence serial number 13 aminoacid sequence after the substitution, additional or flaw aminoacid of sequence expressed that the polypeptide, (8) may the variation area be the sequence serial number 15 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed that (9) to be possible the variation area to be by in the sequence serial number 17 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (10) may the variation area be the sequence serial number 19 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (11) may the variation area be the sequence serial number 21 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (12) may the variation area be the sequence serial number 23 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (13) may the variation area be the sequence serial number 25 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (14) may the variation area be the sequence serial number 27 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (15) by polypeptide that the following aminoacid sequence expressed: In the sequence serial number 2 aminoacid sequences the No. 219 half bladder amino acid had substituted for the aminoacid sequence of C amino acid, in this aminoacid sequence has substituted, attachment either the flaw 1 or aminoacid of sequences several aminoacid; (16) may the variation area be the sequence serial number 29 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (17) may the variation area be the sequence serial number 31 aminoacid sequence or this aminoacid sequence has substituted, attachment either the flaw by in 1 or aminoacid of sequences several aminoacid expresses the polypeptide; (18) may the variation area be the sequence serial number 33 aminoacid sequence or this aminoacid sequence has substituted, attachment either the flaw by in 1 or aminoacid of sequences several aminoacid expresses the polypeptide; (19) may the variation area be the sequence serial number 35 aminoacid sequence or this aminoacid sequence has substituted, attachment either the flaw by in 1 or aminoacid of sequences several aminoacid expresses the polypeptide; (20) may the variation area be by the sequence serial number 37 aminoacid sequences, or in this aminoacid sequence has substituted for the polypeptide that attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (21) may the variation area be the sequence serial number 39 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (22) may the variation area be the sequence serial number 41 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (23) may the variation area be the sequence serial number 43 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (24) may the variation area be the sequence serial number 45 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (25) may the variation area be the sequence serial number 47 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; (26) may the variation area be the sequence serial number 49 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed; And (27) may the variation area be the sequence serial number 51 aminoacid sequence or this aminoacid sequence has substituted for the polypeptide that by, attachment either the flaw 1 or aminoacid of sequences several aminoacid expressed.
[claim4]
4. 1 kinds of medicines use the constituent, it 徴 lies in especially is 1 or 2 includes the human antibody by like the request item Kappa the constituent of light chain complex as the active principle.
[claim5]
5. Like a request item of 4 medicine uses the constituent, it is the anticancer.
[claim6]
6. 1 kinds include the human antibody Kappa the manufacture method of constituent of light chain complex, it 徴 lies in especially has the following step: The performance step, its use contains the performance of gathering nucleotide to use the carrier, in or extracellular performance system because of cell, but makes the above human antibody Kappa the light chain performance, this gathering nucleotide is the code has of human antibody half bladder amino acid residue in the C terminal Kappa the light chain; And the purification step, it is from obtains the performance product to purify the above human antibody in the above performance step Kappa the light chain; And, (a) in the above performance step, is in electing from Yu You the 10th race element, the 11th race element and 12th race element constitute over existence of 1 of under kind metallic ion groups, makes the above human antibody Kappa the light chain performance; Or, (b) will elect, from Yu You the 10th race element, the 11th race element and 12th race element constitute over 1 of the kind metallic ion groups to increase to the above performance step obtain the performance product, and purifies the above human antibody from the obtained mixture Kappa the light chain.
[claim7]
7. Like request item 6 include the human antibody Kappa the manufacture method of constituent of light chain complex, above (b) is the above mixture cultivates 30 minutes ~48 hours later, from this mixture purifies the human antibody Kappa the light chain.
[claim8]
8. Like request item 6 or 7 include the human antibody Kappa the manufacture method of constituent of light chain complex, the above purification step is with 2nd purifies the steps form by the 1st purification step: This 1st purification step was by using contained the tube of column's 1st auxiliaries tube column chromatographic analysis law, from the above performance step obtained the performance product to obtain to contain the above human antibody Kappa the thick purification of light chain, this 2nd purification step was by using contained the tube of column's 2nd auxiliaries tube column chromatographic analysis law, from the thick purification that the above 1st purification step obtained obtains the above human antibody Kappa the purification of light chain, after the above 1st purification step, and before the above 2nd purification step, increased the above metallic ion to the above thick purification.
[claim9]
9. Like request item 8 include the human antibody Kappa the manufacture method of constituent of light chain complex, it is before the above 2nd purification step, will pass through increase above metallic ion the above thick purification cultivation 30 minutes ~48 hours.
[claim10]
10. Like request item 8 include the human antibody Kappa the manufacture method of constituent of light chain complex, it is after the above performance step the above metallic ion increases to the above performance system, further after the above 1st purification step, and before the above 2nd purification step, increases the above metallic ion to the above thick purification.
[claim11]
11. 1 kinds include the human antibody Kappa the manufacture method of constituent of light chain complex, it 徴 lies in especially: In including to elect from Yu You the 10th race element, the 11th race element and 12th race element constitute over solution of 1 in the kind metallic ion groups to cultivate the human antibody Kappa the light chain, takes advantage of this manufacture to include the complex constituent, this compound system 2 above human antibodies Kappa C of terminal's light chain half bladder amino acid residue by the above metallic ion union.
  • 出願人(英語)
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • UDA TAIZO
  • HIFUMI EMI
国際特許分類(IPC)
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close